1. Introduction {#s0005}
===============

Diabetic complications develop at a young age, with persistent hyperglycemia and improper metabolism of protein, lipid, and carbohydrate, thus resulting in defective insulin action and its secretion ([@b0155]). Its prevalence among populace might be due to diet and lifestyle ([@b0105]). Protein Tyrosine Phosphatase 1B (PTP1B) has been objectivized as a mode of treatment for Diabetes Mellitus (DM) ([@b0115]) by revising glucose tolerance, resistance to insulin sensitivity and diet -- induced obesity ([@b0065], [@b0025]).

Currently herbal remedies are highly preferred for DM due to expensive and serious side effects of synthetic antidiabetic drugs ([@b0045], [@b0145]). *Borassus flabellifer* L. (Arecaceae) is a palm tree; it is generally utilized as a stimulant, diuretic, laxative, aphrodisiac; it also possesses antioxidant property ([@b0005], [@b0130], [@b0125], [@b0090], [@b0110]). Serum glucose levels in sucrose-loaded normal rats decreased gradually upon treatment with methanol extract of *Borassus flabellifer* flower ([@b0180]).

Different parts of *B. flabellifer* are used by tribal people for various purposes*.* The male flowers of *B. flabellifer* ([@b0085], [@b0140]) reported that benzene, chloroform, acetone, methanol and ethanol extracts inhibited the growth of pathogenic bacteria.

The juice obtained from the flower stalk was used to treat diabetes ([@b0150]). The fruits of *B. flabellifer* showed antioxidant, antihelmintic, diuretic, antibacterial properties, immunomodulatory and antimalarial properties ([@b0135]). Palm fruit has antioxidant and anti-inflammatory properties. The plant contains different types of phytoconstituents such as vitamins, minerals and polyphenols ([@b0060]).

The present work was carried out to assess the antidiabetic potential of BF-M by downregulating PTP1B expression in pancreas and its effect on glucose and lipid metabolism in diabetic rats.

2. Materials and methods {#s0010}
========================

2.1. Preparation of crude extract {#s0015}
---------------------------------

*Borassus flabellifer* L. (Arecaceae) fruits were gathered from Sirupaniyur Thakka village, Villupuram district, Tamil Nadu, India. The fruits of *B. flabellifer* were authenticated by botanist Dr. C. Muthukumar, Assistant Professor, National College, Trichy. The fresh fruits were chopped into small pieces (800 g) after shade drying and subsequently soaked in 90% methanol. This set up was kept at room temperature (25 ± 2 °C) for 3 days with intermittent shaking. After 3 days the methanol extract was filtered through filter paper. The extract was condensed utilizing rotary vacuum evaporator at 40 °C ([@b0050]). Finally the crude extract (BF-M) was obtained. The collected crude extract yield was around -20g.

2.2. GC-MS analysis of BF-M {#s0020}
---------------------------

The BF-M extract was studied the gas chromatography (GC-MS-QP 2010 \[SHIMADZU). The instrument was equipped with a CPB-capillary column (30.mx 0.25 mm i.d) coated with 5% phynyl with 95% dimethyl siloxane, film thickness 0.2 µm). The temperature program was 70 to 300 ˚with 5˚ per minute. The Injector temperature was 200°; carrier gas was He (20 psi), flow rate was 1.51 ml/min. 1 μl of test sample was injected into the sample receiver with the help of hot needle; split ratio was 10. The instrument was attached with GCMS library, NIST, Wiley. The experiment was carried out at Sargam Laboratory Service, Private Ltd, Chennai-600 089, India ([@b0095]).

2.3. Experimental animals {#s0025}
-------------------------

Healthy adult wistar rats were grown (weighing about 170--190 g) in Central animal house, Entomology Research Institute, Loyola College in suitable environmental condition. The room temperature was (22 ± 2 °C), with relative humidity (45 ± 5 °C) and 12/12 h day/night cycle. All the animals were maintained for seven days fed with standard pellet diet supplied from Sai Durga Feeds and Foods, Bangalore. The animal experiments were approved by the Institutional Animal Ethics Committee (IAEC- ERI-LC-04/10).

### 2.3.1. PTPB1 inhibition assay {#s0030}

Phosphatase activity was analyzed using a substrate namely Para-Nitro Phenyl Phosphate (P-NPP) ([@b0080]). This assay buffer, comprising of glutathione (5 mM), 3, 3-dimethyl glutarate (50 mM) and 1 mM Ethylene Diamine Tetra Acetic Acid (EDTA) was changed in accordance with an ionic nature of 0.15 M by NaCl. The reaction lasted for 60 min. Once the reaction was completed, the ELISA reader (405 nm) was used to measure the enzyme activity.

2.4. Low dose STZ with HFD induced type 2 diabetes {#s0035}
--------------------------------------------------

Healthy adult wistar animals of either sex weighing 180 ± 10 g were fed to standard nourishment feeds and water for 1 week with 12-hour light/dark cycle. After 1 week, the rodents to be subjected to experiment were given a diet (60% fat) except normal control. After 2 weeks on high fat diet, overnight fasted adult albino wistar strain male rats were given freshly prepared STZ (40 mg/kg) (Sigma-Aldrich, Bangalore) through intraperitoneal mode. On the seventh day, those rats which had blood glucose level over 288 mg/dL were considered as diabetic and incorporated into the investigation ([@b0160]).

2.5. Experimental design {#s0040}
------------------------

There were five groups and each group had six rats (n = 6 per group). Ordinary faucet water was utilized as a vehicle. A single dosage of BF-M (100 and 200 mg/kg) was mixed with vehicle and given orally for 21 days. The BF-M dose was selected based on preliminary tests of a variety of doses.

Group I consisted of normal control rats with access to tap water. Group II was diabetic control; Group 3 was diabetic rats treated with BF-M (100 mg/kg) administered orally; Group 4 was diabetic rats treated orally with BF-M (200 mg/kg); Diabetic rats of group 5 were treated with glibenclamide (5 mg/kg) in aqueous solution.

Fasting glucose level was measured once in a week starting from basal level (on the day prior to STZ injection), then on 7^th^, 14^th^, 21^st^ and 28^th^ days after the injection of STZ. Plasma insulin and body weight were measured at basal level, 7th and 28th days of the treatment. Anesthetization of rats with 400 mg/kg Chloral hydrate was done on the final day and their blood was collected.

2.6. Biochemical tests {#s0045}
----------------------

### 2.6.1. Serum glucose level and plasma insulin measurement {#s0050}

The ELISA kit (Life Technologies, India) and glucose oxidase-peroxidase approach had been used to assess the plasma insulin level and blood glucose level respectively ([@b0160]).

### 2.6.2. Estimation of carbohydrate metabolism enzymes {#s0055}

Protocols of [@b0040], [@b0070] were applied to estimate Fructose 1, 6 bisphosphatase and Glucose-6-phosphatase (G-6-P) enzymes.

### 2.6.3. Measurement of liver and muscle glycogen contents {#s0060}

Liver and skeletal muscles were used for the measurement of glycogen level using Anthrone method.

### 2.6.4. Lipid profile measurement {#s0065}

Serum lipid profiles such as total cholesterol (TC), triglycerides (TG), and free fatty acid were measured based on the manufacturer's instructions (Merck, Mumbai, India; Wako Pure Chemicals, Japan) ([@b0035]).

### 2.6.5. Preparation of histological specimens {#s0070}

The pancreas was sliced up and soaked in 10% formalin. The organs were prepared in an elevated arrangement of liquid and inserted in the prepared wax. Serial segments (5 μm) of this organ were taken utilizing a microtome and then mounted on glass slides, recolored with hematoxylin and eosin (H&E) and subjected to microscopic examination.

### 2.6.6. Immunohistochemistry study {#s0075}

For the immunohistochemistry study, pancreas was cleansed away using saline, retained in the preferred percentage of formalin (10%) and then it was embedded with paraffin ([@b0175]). Running water was used to wash the specimen overnight and afterwards separated for sectioning (5 μm in thickness). The processes of de-waxing and incubation on the prepared sample were done at room temperature for 1 h. Phosphate Buffered Saline (PBS) (having 0.5% triton X-100 and 2% ordinary goat serum) was used to protect the samples and kept for 16 h at 4 °C. Again, they were cleansed with PBS. The essential monoclonal antibodies (Mouse anti-EMA, USA) were used for incubating the samples at 4 °C throughout the night. Primary antibody and anti-mouse secondary antibody were bound together and incubated for a period of time. Segments were recolored with H&E. The software, Morphometry image analysis (Bethesda, USA) played an important role in measuring the insulin positive area.

### 2.6.7. Western blot {#s0080}

The expression of PTP1B in pancreatic tissue was analyzed using western blot. The dissected pancreatic tissue was submerged in cold hypotonic lysis buffer solution containing 1 M NaHCO3, 1 M NaN3,0.1 M PMSF, and Protease Inhibitor Cocktail (Calbiochem, SanDiego, CA) and allowed to stand for 30 min. Afterwards, the specimens were subjected to homogenization with high-speed rotational tissue homogenizer (Glas-Col, Terre Hute, IN) and centrifuged at 12,000 RPM for 5 min). Finally the supernatant containing protein was collected and studied further.

The protein (40 mg) was run in 10% (w/v) SDS-PAGE followed by exposure to nitrocellulose membrane. Tween (0.05%) along with Tris buffered saline (TBS) containing 3% skimmed milk powder was used to dip the membrane. Then, primary antibody for PTP1B (Santa Cruz Biochemical, USA) was added and kept at room temperature nearly for 1 h. Then, TBS was used to wash the membrane. After adding the secondary antibody, it was kept at room temperature for 1 h. The counter acting agent receptive groups were exposed using the Amersham product of upgraded chemiluminescence pack and Bio-rad product of ChemiDoc XRS Gel Imager.

### 2.6.8. Statistical evaluation {#s0085}

All the data were calculated using mean ± Standard Error of Mean (SEM). The significant differences between two groups (Version 11.5; SPSS program) were evaluated by T-test. The set values were significant at *p* ≤ 0.05. Each group carried six replications (n = 6).

3. Results {#s0090}
==========

3.1. GC-MS analysis of BF-M {#s0095}
---------------------------

BF-methanol extract was subjected to GC-MS chromatography to assess the chemical constituents. The following compounds were found in the extract; (1) 3, 5-dihydroxy-6-methyl-2, 3-dihydro-4H-pyran-4-one (3.08%)\], (2) 5-hydrxoymethylfurfural (47.56%), (3) guanosine (CAS) guo (21.01%), (4) tetradecanoic acid (1.05%), (5) n-hexadecanoic acid (25.14%), (6) and octadecanoic acid (2.15%) ([Fig. 1](#f0005){ref-type="fig"}). The major compound was 5-hydrxoymethylfurfural.Fig. 1(a) GC-MS analysis of *Borassus flabellifer* fruit methanol extract.

3.2. *In vitro* PTP1B assay {#s0100}
---------------------------

[Table 1](#t0005){ref-type="table"} shows the PTP1B inhibition in the extract of BF-M and agarose. BF-M and Agarose demonstrated noteworthy dosage reliant inhibition of PTP1B catalyst movement; the IC~50~ value was observed to be 23.98 μg/mL and 0.362 μg/mL respectively.Table 1Effect of BF-M on Protein Tyrosine Phosphatase-1B (PTP1B) enzyme activity in *in vitro.*SampleConcentration (μg/mL)(%) InhibitionIC ~50~BF-M520.53 ± 0.2923.981037.77 ± 0.342556.92 ± 0.285077.09 ± 0.6310098.72 ± 0.32Agarbose0.132.14 ± 0.570.3620.561.30 ± 0.84175.34 ± 0.21299.50 ± 0.25[^1][^2]

3.3. Fasting blood glucose and BF-M {#s0105}
-----------------------------------

[Fig. 2](#f0010){ref-type="fig"}(a) and [Table 2](#t0010){ref-type="table"} demonstrate the impacts of BF-M on body weight and fasting blood glucose in STZ-induced diabetic rodents. The fasting blood glucose level significantly increased in STZ-induced diabetic rodents and body weight of the animals in the same group was decreased. Oral administration of BF-M (100 or 200 mg/kg) for 21 days to the diabetic animals increased the body weight and fundamentally diminished fasting blood glucose. After 21 days Glibenclamide treated group showed reduction in glucose level compared to disease control group.Fig. 2(a) Effect of BF-M (100 and 200 mg/kg) on Fasting plasma glucose level in HFD fed-STZ induced diabetic rats. (b) Effect of BF-M on liver and muscle glycogen content in HFD fed-STZ induced diabetic rats. Results are expressed as the mean ± SEM (n = 6). Significant difference between two groups were analysed by Student's *t*-test. a Significantly no different (P \> 0.05) from normal control; b Significantly different (P \< 0.01) from normal control; c Significantly different (P \< 0.05) from diabetic control; d Significantly different (P \< 0.05) from diabetic control; e Significantly different (P \< 0.01) from diabetic control.Table 2Effect of BF-M (100 and 200 mg/kg) on body weight in HFD fed- low STZ induced diabetic rats.TreatmentBody weight (g)InitialFinalNormal control184.10 ± 2.01213.40 ± 2.31Diabetic control185.45 ± 3.10189 ± 5.70[b](#tblfn1){ref-type="table-fn"}Diabetic *+* BF-M (100 mg/kg)191.24 ± 4.21198.50 ± 4.17[c](#tblfn2){ref-type="table-fn"}Diabetic *+* BF-M (200 mg/kg)189.30 ± 5.10210.50 ± 5.75[d](#tblfn3){ref-type="table-fn"}Diabetic + glibenclamide (5 mg/kg)190.62 ± 3.70214.37 ± 4.12[d](#tblfn3){ref-type="table-fn"}[^3][^4][^5][^6]

3.4. BF-M effect on plasma insulin {#s0110}
----------------------------------

[Table 3](#t0015){ref-type="table"} elucidates the effects of BF-M on plasma insulin in STZ-treated rats and normal control. Plasma insulin levels in diabetic rats were decreased significantly in comparison with the normal control group. BF-M treated diabetic rats showed increased plasma insulin levels in comparison to diabetic controls.Table 3Effect of BF-M (100 and 200 mg/kg) on plasma insulin level in HFD fed-STZ induced diabetic rats.TreatmentPlasma insulin level7th day28th dayNormal control125.11 ± 0.87131.09 ± 1.88Diabetic control54.66 ± 1.89[b](#tblfn4){ref-type="table-fn"}49.49 ± 0.89[b](#tblfn4){ref-type="table-fn"}Diabetic *+* BF-M (100 mg/kg)52.19 ± 1.96[b](#tblfn4){ref-type="table-fn"}84.85 ± 1.27[c](#tblfn5){ref-type="table-fn"}Diabetic *+* BF-M (200 mg/kg)51.65 ± 1.73[b](#tblfn4){ref-type="table-fn"}112.29 ± 1.09[d](#tblfn6){ref-type="table-fn"}Diabetic + glibenclamide (5 mg/kg)49.52 ± 1.38[b](#tblfn4){ref-type="table-fn"}117.70 ± 0.98[d](#tblfn6){ref-type="table-fn"}[^7][^8][^9][^10]

### 3.4.1. Enzymes of carbohydrate metabolism {#s0115}

[Table 4](#t0020){ref-type="table"} reveals the activities of enzymes associated with carbohydrate metabolism in control and STZ induced diabetic animals. The activities of Fructose 1, 6 bisphosphatase and Glucose-6-Phospatase were increased in diabetic rodents compared to normal control. In animals administered with BF-M (100 or 200 mg/kg) for 21 day, the activities of Fructose 1, 6 bisphosphatase and Glucose-6-phosphatase were significantly reduced when compared to diabetic control.Table 4Effect of BF-M (100 and 200 mg) induced diabetic rats after 21 days study.GroupsGlucose 6 phosphatase (μ mole of Pi liberated/min/mg protein)Fructose 1,6 bisphosphatase (µ mole of Pi liberated/min/mg protein)Normal control0.15 ± 0.0067.20 ± 0.71Diabetic control0.34 ± 0.122[b](#tblfn7){ref-type="table-fn"}20.36 ± 0.91[b](#tblfn7){ref-type="table-fn"}Diabetic *+* BF-M (100 mg/kg)0.27 ± 0.007[c](#tblfn8){ref-type="table-fn"}14.67 ± 0.82[c](#tblfn8){ref-type="table-fn"}Diabetic *+* BF-M (200 mg/kg)0.24 ± 0.006[c](#tblfn8){ref-type="table-fn"}9.28 ± 0.50[c](#tblfn8){ref-type="table-fn"}Diabetic + Glibenclamide (5 mg/kg)0.23 ± 0.014[d](#tblfn9){ref-type="table-fn"}8.94 ± 0.68[d](#tblfn9){ref-type="table-fn"}[^11][^12][^13][^14]

3.5. *BF*-M *effect on liver and muscle glycogen contents* {#s0120}
----------------------------------------------------------

[Fig. 2](#f0010){ref-type="fig"}(b) demonstrates the effects of BF-M on liver substance and muscle glycogen in STZ induced diabetic rodents. Diabetic rodents fed with BF-M (100 or 200 mg/kg) for 21 days indicated critical increments in glycogen substance when compared to diabetic control.

3.6. *Effects of BF*-M *on total cholesterol, triglycerides and free fatty acid* {#s0125}
--------------------------------------------------------------------------------

[Fig. 3](#f0015){ref-type="fig"}(a), (b) and (c) demonstrate the increased level of triglycerides, free unsaturated fat and serum total cholesterol in diabetic control rodents. On the other hand diabetic rodents treated with 100 or 200 mg/kg of BF-M had essentially low total cholesterol and free unsaturated compared to diabetic control rats.Fig. 3(a,b,c). Effect of BF-M on Total cholesterol, Triglycerides and Free fatty acids in HFD fed-STZ induced diabetic rats. Results are expressed as the mean ± SEM (n = 6). Significant difference between two groups were analysed by Student's *t*-test. b Significantly different (P \< 0.01) from normal control; c Significantly different (P \< 0.05) from diabetic control; d Significantly different (P \< 0.05) from diabetic control.

3.7. PTP1B expression in pancreatic tissue {#s0130}
------------------------------------------

The impact of BF-M on PTP1B in pancreatic tissue was analyzed using western blot ([Fig. 4](#f0020){ref-type="fig"}). There was a high expression of PTP1B in the pancreatic tissues of the diabetic rats; however the BF-M and glibenclamide treated groups showed decreased levels of PTP1B.Fig. 4Effect of BF-M on PTP1B expression on normal and HFD fed-STZ induced diabetic rats. Results are expressed as the mean ± SEM (n = 6). Significant differences between two groups were analyzed by Student's *t*-test. b Significantly different (P \< 0.01) from normal control; c Significantly different (P \< 0.05) from diabetic control; d Significantly different (P \< 0.05) from diabetic control; e Significantly different (P \< 0.01) from diabetic control.

3.8. H&E staining {#s0135}
-----------------

The light microscopy photographs of normal control group rats showed normal architecture of pancreatic islets [Fig. 5a](#f0025){ref-type="fig"} (A). Diabetic controls exhibited degenerative changes, necrotic changes, infiltration of acute inflammatory cells, interstitial edema, and vacuoles [Fig. 5a](#f0025){ref-type="fig"} (B). BF-M (100 or 200 mg/kg) treated diabetic rats showed markedly less pancreatic vascular necrosis compared to diabetic controls [Fig. 5a](#f0025){ref-type="fig"} (C-D). Glibenclamide (5 mg/kg) treated diabetic rats exhibited similar patterns as those of normal controls [Fig. 5a](#f0025){ref-type="fig"} (E)Fig. 5(a) Histopathological study of normal and HFD fed-STZ induced diabetic rat pancreas. A-Normal pancreas; B- Diabetic control; C- Diabetic +BF-M (100 mg/kg); D- Diabetic + 66 BF-M (200 mg/kg); E- Diabetic + Glibenclamide (5 mg/kg). (b). Immunohistochemical analysis of normal and ^.^HFD fed-STZ induced diabetic rat pancreas. A-Healthy β-cells were seen Langerhans in the islets of normal control group, B -- Weak insulin immuno reactivity can be seen in a few β-cells in the islet of Langerhans in Diabetic control, C- few β-cells in some islets displaying insulin immunopositive in very small granules of diabetic rats treated with BF-M 100 mg/kg; Diabetic animal treated with BF-M 200 mg/kg and glibenclamide 5 mg/kg protected the majority of β-cells in the islet of Langerhans and gave strong straining with anti-insulin antibody, immunoperoxidase and hemotoxylin. (c) Relationship between insulin immunopositive and positive islets area (%) of HFD fed-STZ Induced diabetic rats. Results are expressed as the mean ± SEM of the number β-cells detected in each islet section. a Significantly different (P \< 0.01) from normal control; b Significantly different (P \< 0.05) from diabetic control; c Significantly different (P \< 0.01) from diabetic control.

3.9. Immunohistological study {#s0140}
-----------------------------

In control rats normal β-cells were found in the islets of Langerhans upon immunohistochemical staining \[[Fig. 5b](#f0025){ref-type="fig"} (A)\]. In contrast, diabetic rats exhibited β-cells with weak insulin immunoreactivity \[[Fig. 5b](#f0025){ref-type="fig"} (B)\]. BF-M (100 mg/kg) treated diabetic rodents showed some active β-cells \[[Fig. 5b](#f0025){ref-type="fig"} (C)\]. BF-M (200 mg/kg) and glibenclamide (5 mg/kg) treated diabetic rodents showed more active β-cells \[([Fig. 5b](#f0025){ref-type="fig"} (D, E)\]. Image analysis revealed less than 3% of active islets area in diabetic control, whereas rats treated with 100 and 200 mg/kg BF-M, exhibited 30.73 ± 12.0 and 55.08 ± 7.21 active β-cell respectively. We found that rats treated with 5 mg/kg glibenclamide exhibited more *active* (80.00 ± 8.20) β-cells than BF-M (200 mg/kg) treated rats ([Fig. 5c](#f0025){ref-type="fig"}).

4. Discussion {#s0145}
=============

Glucose storage and insulin levels are the major factors with respect to Type 2 diabetes. Further, glucose storage is increased in response to insulin resistance, prompting hyperinsulinemia and hyperglycemia ([@b0010]). PTP1B influences glucose homeostasis regulation and several physiological functions, where its expression has direct connection to hyperglycemia ([@b0030], [@b0120]). PTP1B is the main insulin sensitivity regulator and it has been confirmed by whole-body knockout in mice. The target regulator PTP1B has used for the treatment of diabetes and obesity ([@b0015]). Dose dependency study showed that BF-M inhibited PTP1B effectively with IC~50~ value of 23.98 μg/mL; more over GC-MS analysis revealed the presence of n-hexadecanoic acid (25.14%), octadecanoic acid (2.15%) and tetradecanoic acid (1.05%) whose PTP1B inhibiting effects are well documented. This proves that BF-M is an effective PTP1B inhibitor ([@b0055]). A couple of studies have shown that the HFD fed rats developed insulin protection; meanwhile streptozotocin has been known to devastate the pancreatic β-cells specifically ([@b0185]). Hence, using low dosage of STZ with high-fat diet nearly mimics the diabetes metabolic qualities in rodents; this model was used to assess the impact of BF-M on diabetes.

HFD fed STZ induced diabetic rats showed increased levels of blood glucose, decreased levels of insulin and amplified expression of PTP1B. Insulin signaling is highly controlled by phosphorylation status of several components and pathways. The most important phosphatase is PTP1B which regulates the insulin signaling cascade and inhibits insulin receptors (IR and IRS 1) by direct phosphorylation affecting the insulin secretion which results in the increased glucose level during diabetic state ([@b0170]). In the current study, BF-M showed a substantial rise in insulin level and significant reduction in blood glucose level. Furthermore, Western blot analysis of BF-M treated diabetic rats revealed the reduction of PTP1B expression significantly. From this result we speculated that decreased PTP1B expression by BF-M in pancreas could lead to enhanced beta cell mass which eventually enhanced glucose stimulated insulin release which brought down the blood glucose level significantly ([@b0075]). It is well known that the extracellular signal-regulated protein kinase 1/2 (ERK1/2) is activated by PTP1B. In addition, AKT phosphorylation helps proapoptic protein degradation and regulates the β cell survival ([@b0100]). Our histopathological analysis of pancreas strongly correlated with this concept, where BF-M treated rats' pancreas exhibited increased β cell mass. Furthermore, the glycemic index of HFD fed STZ treated diabetic rats gradually came back to the normal range due to treatment with BF-M.

In our study, BF-M was administered orally to the diabetic rats and it significantly increased the glycogen level both in liver and muscle clearly showing that it can act through the modulation of PTP1B. Interestingly, a study has shown that diminished PTP1B expression enhanced the insulin stimulated glycogen synthesis in both muscle and tissue ([@b0020]).

Diabetes is linked with significant changes in the lipoprotein profile and plasma lipid. Increased levels of TC, TG and FFAs are seen in uncontrolled type 2 diabetes. TC, TG and FFAs contribute to coronary artery disease and assume a noteworthy role in the pathogenesis of insulin protection. Treatment with BF-M significantly decreased serum TG, FFAs and TC probably through inhibition of PTP1B expression; since PTP1B regulates lipogenesis and hypertriglyceridemia, its inhibition might reduce TG, FFAs and TC ([@b0165]).

In conclusion, this study highlighted the ability of BF-M in successfully reducing the effect of diabetes in HFD fed STZ induced diabetic rats by inhibiting the PTP1B expression *in vivo* and *in vitro*. GC-MS analysis of BF-M revealed that several secondary metabolites were responsible for PTP1B inhibition. BF-M, a potent PTP1B inhibitor, enhanced the insulin secretion leading to noteworthy lessening in blood glucose level, through which BF-M normalized altered lipid and glucose metabolism. Furthermore improved glycemic control positively influenced food intake and body weight. Immunohistopathological studies also correlated with the findings. Hence, diabetes and its respective complications can be treated using BF-M. Further investigation is necessary to reveal the clear mechanism of action of BF-M.
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[^1]: Values are expressed as mean ± SEM (% inhibition) and mean (IC~50~) n = 6.

[^2]: B-F: Borassus flabellifer Methanol extract Agarbose: Standard.

[^3]: Results are expressed as the mean ± S.E.M in each group (n = 6). Significant difference between two groups were analysed by Student's *t*-test.

[^4]: Significantly different (*P* \< 0.01) from normal control.

[^5]: Significantly different (*P* \< 0.05) from diabetic control.

[^6]: Significantly different (*P* \< 0.01) from diabetic control.

[^7]: Results are expressed as the mean ± S.E.M in each group (n = 6). Significant difference between two groups were analysed by Student's *t*-test.

[^8]: Significantly different (*P* \< 0.01) from normal control.

[^9]: Significantly different (*P* \< 0.05) from diabetic control.

[^10]: Significantly different (*P* \< 0.01) from diabetic control.

[^11]: Results are expressed as the mean ± S.E.M in each group (n = 6). Significant difference between two groups were analysed by Student's *t*-test.

[^12]: Significantly different (*P* \< 0.01) from normal control.

[^13]: Significantly different (*P* \< 0.05) from diabetic control.

[^14]: Significantly different (*P* \< 0.01) from diabetic control.
